Device for an electrophysiology procedure
A quantum cardiac electrophysiology device comprising an array of consumable half-ferromagnetic active electrodes connected to an array of semiconductor of half-ferromagnetic selector switches over an array of half-ferromagnetic resistors to a neutral charges out of the heart, by casting and/or inking the arrhythmic substrate of an arrhythmia by the electrophysiology quantum entan- glement of said arrhythmic substrate.
The current International Patent Application is a continuation of PCT/IB2020/055111 entirely embedded herein as reference, that claims priority to PCT/EP2019/086922 and EP19180033.3.
In one first embodiment, an electrophysiology catheter device, a catheter device and a method were provided to map one arrhythmic substrate to out-channel electrical current out from the arrhythmic substrate to interrupt the arrhythmia or to render it not reproducible.
In one second embodiment, the electrophysiology catheter device, the catheter device were provided as internal component of an implantable cardiac device such as pacemaker, cardiac defibrillator or cardiac contractility modulation device. An innovative cardiac implantable device configured to be able to out-channel electrical current out from the heart was provided.
Exceeding by far all prior art, one first embodiment is provided wherein each of active electrodes (121, 122, 123, 124 . . . ) of the electrophysiology device and catheter device embedded herein as reference is further on configured to be a consumable active electrode, to be able to decay at the level of the arrhythmic substrate during mapping, wherein said decay provides an innovative method of inking the arrhythmic substrate. Further on, each of said consumable active electrodes may be configured to be a half-ferromagnetic electrode. The sum of the decay of every consumable active electrode can not exceed the amount of inking the arrhythmic substrate and the amount of inking the arrhythmic substrate can not exceed the sum of the decay of every consumable active electrode. This innovative method of inking the arrhythmic substrate by said decay of said consumable active electrode(s) within the arrhythmic substrate, as well as the method of inking the arrhythmic substrate with a staining ink previously described as “therapy” in claims 4-9 embedded herein as reference and not searched in PCT/IB2020/055111, are both complementary methods of inking the substrate that thoroughly satisfy the magnetic field integration into mapping and inking the arrhythmic substrate by either remote magnetically navigable or conventionally navigable mapping catheters.
Additionally and exceeding by far all prior art, second selector switch (155) embedded herein as reference may be configured to be a second selector switch array (155-array) wherein each second selector switch from said second selector switch array may be further on configured to be a second magnetic tunnel selector switch. The resistor (151) embedded herein as reference may be configured to be a resistor array (151-array), bijectively connected to said second selector switch array (155-array).
Similarly and exceeding by far all prior art, first selector switch (156) embedded herein as reference may be configured to be a first selector switch array (156-array) wherein each first selector switch from said first selector switch array may be further on configured to be a first magnetic tunnel selector switch. The sensor device (160) embedded herein as reference may be configured to be a sensor device array (160-array), bijectively connected to said first selector switch array (156-array).
Furthermore and exceeding by far all prior art, said first magnetic tunnel selector switch array (156-array) is configured to collapse the quantum superposition of the electric and/or magnetic charges at the level of the arrhythmic substrate, by measuring of at least one negative differential resistance (NDR) at the level of at least one biological qubit of substrate to collapse the substrate and interrupt the arrhythmia. Whereas the measurement of at least one NDR collapses the substrate de facto during mapping, the substrate remains collapsed beyond the time frame of mapping when inking applies, wherein said inking represents said decay of said consumable active electrode(s) within the substrate. For those skilled in the art, said arrhythmia is intended in a broader sense, involving both a pathological conduction as well as a pathological lack of conduction at the level of the arrhythmic substrate. Similarly, interruption of said arrhythmia involves interrupting the pathological conduction or interrupting the pathological lack of a conduction by swapping an alternate current path.
The operator decides during the procedure, according to the type of the arrhythmia being observed and his/her own consciousness and/or expertise, in which way set or change the setting of selector switches to provide NDR measurements at the level of bio-qubits of substrate that collapse the substrate, to ink them to maintain the substrate collapsed to permanently avoid the arrhythmia. Additionally, It is always preferably to let the patient maintain an acceptable level of consciousness during the procedure avoiding if possible one deep sedation while arrhythmic substrate is being mapped by the operator. In further embodiments a patient-operator(s) brain-heart-brain(s) quantum superposition may be discussed.
Changing the setting of first and second magnetic tunnel selector switches may involve an automation process in some other embodiments. Remote magnetic tunnel selector switch arrays, separated even by large distances may be configured to be entangled as does the measurement of the NDR at the level of the arrhythmic substrate that collapses the arrhythmic substrate.
According to the readings of the sensor device array and according to the occurrent setting of the innovative selector switches, a cast of the arrhythmic substrate is provided in decoherence from the substrate itself. Further on, this allows inking of similar and nonlocal arrhythmic substrates, according to the innovative method depicted herein, by said decay of said consumable active electrodes at the level of the arrhythmic substrate. Exceeding all prior art by far, an innovative method is provided to out-tunnelling electric and/or magnetic current out from the heart in general, and out from the arrhythmic substrate in particular, provided that mapping is/was provided and cast is available. The innovative method is provided preferably by a single shot injection into the vascular system or into the pericardial space, using conventional access points. Multiple, not simultaneous, but preferably spaced in time single shot injections may be also provided.
In one second embodiment and exceeding by far all prior art, the inked-in said collapsed arrhythmic substrate is provided as a quantum built-in cardiac implantable device, locally entangled with the NDR bio-qubits of said collapsed arrhythmic substrate. Said built-in quantum cardiac implantable device may be further on configured to be programmable with SQUID devices.
In the following, the invention will be described by way of example, without limitation of the general invention concept, on examples of embodiments with reference to the drawings.
List of reference numerals
110: catheter device
120: distal end
121-124: consumable distal electrode array
126: low resistive wires
130: proximal end
131: connectors
140: flexible shaft
141: flexible wire
150: control unit
151-array: resistor array
156-array: first magnetic tunnel selector switch array
155-array: second magnetic tunnel selector switch array
160-array: sensor device array
161-array: voltage meter array
161-array: current meter array
170: neutral electrode
180: handle
181, 182: operating elements
200: heart
300: quantum built-in implantable cardiac device
310: tip assembly
360: additional mapping catheter
Although the invention has been illustrated and described in detail by the embodiments explained above, it is not limited to these embodiments. Other variations may be derived by the skilled person without leaving the scope of the attached claims.
In addition, numerical values applied (number of consumable active electrodes, units within arrays) may include the exact values as well as a tolerance interval, unless this is explicitly excluded.
Features shown in the embodiments, in particular in different embodiments, may be combined or substituted without leaving the scope of the invention.
Claims
1. A quantum cardiac electrophysiology device, comprising:
- A consumable active electrodes array, wherein each said consumable electrode may be configured to be half-ferromagnetic;
- A first selector switch array (156-array) commutatively connected to the consumable active electrode array, wherein each first selector switch from said first selector switch array is further on configured to be a first magnetic tunnel selector switch wherein said first magnetic tunnel selector switch may be configured to be semiconductor, half-ferromagnetic or both;
- A second selector switch array (155-array) commutatively connected to the consumable active electrode array, wherein each second selector switch from said second selector switch array is further on configured to be a second magnetic tunnel selector switch wherein said second magnetic tunnel selector switch may be configured to be semiconductor, half-ferromagnetic or both;
- A resistor array (151-array), bijectively connected to said second selector switch array (155-array) wherein said half-ferromagnetic resistors are in anti-parallel state to the heart magnetic field provided by the myocardial band;
- A sensor device array (160-array) configured to be bijectively connected to said first selector switch array (156-array).
2. A method of inking a collapsed arrhythmic substrate wherein said inking is the decay of at least part of at least one consumable active electrodes of claim 1 selectively connected to at least one said first magnetic tunnel selector switch of claim 1, wherein said decay within said collapsed arrhythmic substrate is provided when at least one negative differential resistance (NDR) of at least one biological qubit of said collapsed arrhythmic substrate was measured.
3. A method of inking a collapsed arrhythmic substrate with a half-ferromagnetic staining ink wherein said half-ferromagnetic staining ink is provided and is delivered from an external can to said collapsed arrhythmic substrate through the internal lumen of a mapping catheter or optionally through the lumen of an additional mapping catheter when at least one negative differential resistance (NDR) of at least one biological qubit of said collapsed arrhythmic substrate was measured.
4. A method of inking a not yet collapsed arrhythmic substrate with a half-ferromagnetic staining ink, wherein said half-ferromagnetic staining ink is provided and configured to selectively collapse the substrate where at least one negative differential resistance (NDR) of at least one biological qubit of said not yet collapsed substrate is provided as said half-ferromagnetic staining ink applies and is entangled at said not yet collapsed arrhythmic substrate, wherein said half-ferromagnetic staining ink is delivered into the vascular system or into the pericardial space using conventional access points.
5. The methods of claims 2-4 wherein the inked-in collapsed arrhythmic substrate is a quantum built-in implantable cardiac device, locally entangled within said collapsed arrhythmic substrate and being configured to be programmable by quantum magnetic interference or SQUID devices.
Type: Application
Filed: Dec 20, 2020
Publication Date: Nov 3, 2022
Inventor: Bogdan Gabriel Ionescu (Cologne)
Application Number: 17/280,876
